Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations

Puma Biotechnology PBYI will host a conference call at 1:30 p.m. PST (4:30 p.m. EST) on Monday, December 23, 2013, to provide an update on its clinical trials of PB272 (neratinib) in cancer patients with activating HER2 mutations. This includes the Company's ongoing trials of neratinib in (1) patients with HER2 mutated non-small cell lung cancer; (2) patients with HER2-negative breast cancer who have a HER2 mutation; and (3) patients with solid tumors who have an activating HER2 mutation. See full press release